Evidence map›Paper›PMID 28862704›Full record

Trial reportLeukemia2017

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

T P Hughes, B Leber, F Cervantes, N Spector, R Pasquini, N C D Clementino, A P Schwarer, P E Dorlhiac-Llacer, F-X Mahon, D Rea and 8 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

T P HughesDivision of Haematology, SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
B LeberClinical Pathology, McMaster University, Hamilton, Ontario, Canada.
F CervantesDepartment of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
N SpectorDepartamento de Clínica Médica/FM, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
R PasquiniDivision of Hematology and Medical Oncology, Federal University of Paraná, Curitiba, Brazil.
N C D ClementinoHospital Das Clinicas da UFMG, Belo Horizonte, Brazil.
A P SchwarerDepartment of Hematology, Alfred Hospital, Melbourne, Victoria, Australia.
P E Dorlhiac-LlacerDepartment of Hematology, Hospital das Clinicas FMUSP, São Paulo, Brazil.
F-X MahonLaboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Université Victor Ségalen, Bordeaux, France.
D ReaUnité de Thérapie Cellulaire et Clinique Transfusionnelle, Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, Paris, France.
A Guerci-BreslerDepartment of Hematology, Brabois Hospital, Vandoeuvre-lès-Nancy, Vandoeuvre, France.
S Kamel-ReidClinical Laboratory Genetics, Genome Diagnostics, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.
I BenditHematology Unit, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
S AcharyaNovartis Healthcare Pvt Ltd, Hyderabad, India.
T GlynosNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
D DalalNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
S BranfordLeukaemia Unit, Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide, Adelaide, South Australia, Australia.
J H LiptonBlood and Marrow Transplant Service, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsCross-Over StudiesFusion Proteins, bcr-ablHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsPyrimidinesAntineoplastic AgentsFusion Proteins, bcr-ablImatinib MesylatenilotinibProtein Kinase InhibitorsPyrimidines

Identifiers

PMID28862704
PMCPMC5668492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.